These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 37531338)

  • 1. Effect of any form of steroids in comparison with that of other medications on the duration of olfactory dysfunction in patients with COVID-19: A systematic review of randomized trials and quasi-experimental studies.
    Winn PZ; Hlaing T; Tun KM; Lei SL
    PLoS One; 2023; 18(8):e0288285. PubMed ID: 37531338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.
    Webster KE; O'Byrne L; MacKeith S; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD013877. PubMed ID: 36063364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    O'Byrne L; Webster KE; MacKeith S; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD013876. PubMed ID: 36062970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different types of intranasal steroids for chronic rhinosinusitis.
    Chong LY; Head K; Hopkins C; Philpott C; Burton MJ; Schilder AG
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011993. PubMed ID: 27115215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial.
    Abdelalim AA; Mohamady AA; Elsayed RA; Elawady MA; Ghallab AF
    Am J Otolaryngol; 2021; 42(2):102884. PubMed ID: 33429174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Corticosteroid Treatment on Recovery of Long-Term Olfactory Dysfunction Due to COVID-19.
    Hosseinpoor M; Kabiri M; Rajati Haghi M; Ghadam Soltani T; Rezaei A; Faghfouri A; Poustchian Gholkhatmi Z; Bakhshaee M
    Laryngoscope; 2022 Nov; 132(11):2209-2216. PubMed ID: 36054369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.
    Singh CV; Jain S; Parveen S
    Am J Otolaryngol; 2021; 42(3):102892. PubMed ID: 33493729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial.
    Kasiri H; Rouhani N; Salehifar E; Ghazaeian M; Fallah S
    Int Immunopharmacol; 2021 Sep; 98():107871. PubMed ID: 34147912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis.
    Chong LY; Head K; Hopkins C; Philpott C; Schilder AG; Burton MJ
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011996. PubMed ID: 27115217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    O'Byrne L; Webster KE; MacKeith S; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013876. PubMed ID: 34291813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.
    Webster KE; O'Byrne L; MacKeith S; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013877. PubMed ID: 34291812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid nasal irrigation as early treatment of olfactory dysfunction in COVID-19: A prospective randomised controlled trial.
    Tragoonrungsea J; Tangbumrungtham N; Nitivanichsakul T; Roongpuvapaht B; Tanjararak K
    Clin Otolaryngol; 2023 Mar; 48(2):182-190. PubMed ID: 36336851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Post-Infectious Anosmia and Hyposmia: A Systematic Review.
    Nag AK; Saltagi AK; Saltagi MZ; Wu AW; Higgins TS; Knisely A; Ting JY; Illing EA
    Ann Otol Rhinol Laryngol; 2023 Jul; 132(7):806-817. PubMed ID: 35959948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical corticosteroids applied with a squirt system are more effective than a nasal spray for steroid-dependent olfactory impairment.
    Shu CH; Lee PL; Shiao AS; Chen KT; Lan MY
    Laryngoscope; 2012 Apr; 122(4):747-50. PubMed ID: 22302665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic use of steroids in non-chronic rhinosinusitis olfactory dysfunction: a systematic evidence-based review with recommendations.
    Yan CH; Overdevest JB; Patel ZM
    Int Forum Allergy Rhinol; 2019 Feb; 9(2):165-176. PubMed ID: 30472771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic options of post-COVID-19 related olfactory dysfunction: a systematic review and meta-analysis.
    Asvapoositkul V; Samuthpongtorn J; Aeumjaturapat S; Snidvongs K; Chusakul S; Seresirikachorn K; Kanjanaumporn J
    Rhinology; 2023 Feb; 61(1):2-11. PubMed ID: 36173148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial.
    Di Stadio A; D'Ascanio L; Vaira LA; Cantone E; De Luca P; Cingolani C; Motta G; De Riu G; Vitelli F; Spriano G; De Vincentiis M; Camaioni A; La Mantia I; Ferreli F; Brenner MJ
    Curr Neuropharmacol; 2022; 20(10):2001-2012. PubMed ID: 35450527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial.
    Di Stadio A; Gallina S; Cocuzza S; De Luca P; Ingrassia A; Oliva S; Sireci F; Camaioni A; Ferreli F; Mercante G; Gaino F; Pace GM; La Mantia I; Brenner MJ
    Eur Arch Otorhinolaryngol; 2023 Nov; 280(11):4949-4961. PubMed ID: 37380908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
    Kew KM; Dias S; Cates CJ
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.